13 results on '"Dubey, Sheri A."'
Search Results
2. Comparative Cell-Mediated Immunogenicity of DNA/DNA, DNA/Adenovirus Type 5 (Ad5), or Ad5/Ad5 HIV-1 Clade B gag Vaccine Prime-Boost Regimens
- Author
-
Asmuth, David M., Brown, Elizabeth L., DiNubile, Mark J., Sun, Xiao, Rio, Carlos del, Harro, Clayton, Keefer, Michael C., Kublin, James G., Dubey, Sheri A., Kierstead, Lisa S., Casimiro, Danilo R., Shiver, John W., Robertson, Michael N., Quirk, Erin K., and Mehrotra, Devan V.
- Published
- 2010
3. Safety and Immunogenicily of a Replication-Incompetent Adenovirus Type 5 HIV-1 Clade B Gag/pol/nef Vaccine in Healthy Adults
- Author
-
Priddy, Frances H., Brown, Deborah, Kublin, James, Monahan, Kathleen, Wright, David P., Lalezari, Jacob, Santiago, Steven, Marmor, Michael, Lally, Michelle, Novak, Richard M., Brown, Stephen J., Kulkarni, Priya, Dubey, Sheri A., Kierstead, Lisa S., Casimiro, Danilo R., Mogg, Robin, DiNubile, Mark J., Shiver, John W., Leavitt, Randi Y., Robertson, Michael N., Mehrotra, Devan V., and Quirk, Erin
- Published
- 2008
- Full Text
- View/download PDF
4. Cross-Reactivity of Anti-HIV-1 T Cell Immune Responses among the Major HIV-1 Clades in HIV-1-Positive Individuals from 4 Continents
- Author
-
Coplan, Paul M., Gupta, Swati B., Dubey, Sheri A., Pitisuttithum, Punnee, Nikas, Alex, Mbewe, Bernard, Vardas, Efthyia, Schechter, Mauro, Kallas, Esper G., Freed, Dan C., Fu, Tong-Ming, Mast, Christopher T., Puthavathana, Pilaipan, Kublin, James, Brown Collins, Kelly, Chisi, John, Pendame, Richard, Thaler, Scott J., Gray, Glenda, Mcintyre, James, Straus, Walter L., Condra, Jon H., Mehrotra, Devan V., Guess, Harry A., Emini, Emilio A., and Shiver, John W.
- Published
- 2005
5. Determinants of antibody persistence across doses and continents after single-dose rVSV-ZEBOV vaccination for Ebola virus disease: an observational cohort study
- Author
-
Huttner, Angela, Agnandji, Selidji Todagbe, Combescure, Christophe, Fernandes, José F, Bache, Emmanuel Bache, Kabwende, Lumeka, Ndungu, Francis Maina, Brosnahan, Jessica, Monath, Thomas P, Lemaître, Barbara, Grillet, Stéphane, Botto, Miriam, Engler, Olivier, Portmann, Jasmine, Siegrist, Denise, Bejon, Philip, Silvera, Peter, Kremsner, Peter, Siegrist, Claire-Anne, Krishna, Sanjeev, Addo, Marylyn M., Becker, Stephan, Krähling, Verena, Njuguna, Patricia, Kieny, Marie-Paule, Ahmed, Rafi, Anderson, Jenna, Auderset, Floriane, Borgianni, Luisa, Ciabattini, Annalisa, Haks, Marielle C., Harandi, Ali, Heppner, Donald Gray, Gerlini, Alice, Medaglini, Donata, Ottenhoff, Tom H. M., Pejoski, David, Page, Mark, Pozzi, Gianni, Santoro, Francesco, Dubey, Sheri, Fernandes, José F., Nakaya, Helder, Orourke, Fiona, Rothenberger, Sylvia, Vebcon, VSV-EBOVAC, and VSV-EBOPLUS, Consortia
- Subjects
Adult ,Male ,0301 basic medicine ,medicine.medical_specialty ,viruses ,ddc:616.07 ,Antibodies, Viral ,medicine.disease_cause ,Medication Adherence ,Persistence (computer science) ,Cohort Studies ,03 medical and health sciences ,Immunity ,Internal medicine ,parasitic diseases ,medicine ,Humans ,Ebola Vaccines ,Ebola virus ,ddc:618 ,Dose-Response Relationship, Drug ,biology ,business.industry ,Hemorrhagic Fever, Ebola ,Middle Aged ,Ebolavirus ,Kenya ,3. Good health ,Clinical trial ,Vaccination ,030104 developmental biology ,Infectious Diseases ,biology.protein ,Female ,Observational study ,Antibody ,business ,Switzerland ,Cohort study - Abstract
BACKGROUND: The recombinant vesicular stomatitis virus (rVSV) vaccine expressing the Zaire Ebola virus (ZEBOV) glycoprotein is efficacious in the weeks following single-dose injection, but duration of immunity is unknown. We aimed to assess antibody persistence at 1 and 2 years in volunteers who received single-dose rVSV-ZEBOV in three previous trials. METHODS: In this observational cohort study, we prospectively followed-up participants from the African and European phase 1 rVSV-ZEBOV trials, who were vaccinated once in 2014-15 with 300 000 (low dose) or 10-50 million (high dose) plaque-forming units (pfu) of rVSV-ZEBOV vaccine to assess ZEBOV glycoprotein (IgG) antibody persistence. The primary outcome was ZEBOV glycoprotein-specific IgG geometric mean concentrations (GMCs) measured yearly by ELISA compared with 1 month (ie, 28 days) after immunisation. We report GMCs up to 2 years (Geneva, Switzerland, including neutralising antibodies up to 6 months) and 1 year (Lambaréné, Gabon; Kilifi, Kenya) after vaccination and factors associated with higher antibody persistence beyond 6 months, according to multivariable analyses. Trials and the observational study were registered at ClinicalTrials.gov (Geneva: NCT02287480 and NCT02933931; Kilifi: NCT02296983) and the Pan-African Clinical Trials Registry (Lambaréné PACTR201411000919191). FINDINGS: Of 217 vaccinees from the original studies (102 from the Geneva study, 75 from the Lambaréné study, and 40 from the Kilifi study), 197 returned and provided samples at 1 year (95 from the Geneva study, 63 from the Lambaréné, and 39 from the Kilifi study) and 90 at 2 years (all from the Geneva study). In the Geneva group, 44 (100%) of 44 participants who had been given a high dose (ie, 10-50 million pfu) of vaccine and who were seropositive at day 28 remained seropositive at 2 years, whereas 33 (89%) of 37 who had been given the low dose (ie, 300 000 pfu) remained seropositive for 2 years (p=0·042). In participants who had received a high dose, ZEBOV glycoprotein IgG GMCs decreased significantly between their peak (at 1-3 months) and month 6 after vaccination in Geneva (p0·05). Neutralising antibodies seem to be less durable, with seropositivity dropping from 64-71% at 28 days to 27-31% at 6 months in participants from the Geneva study. INTERPRETATION: Antibody responses to single-dose rVSV-ZEBOV vaccination are sustained across dose ranges and settings, a key criterion in countries where booster vaccinations would be impractical. FUNDING: The Wellcome Trust and Innovative Medicines Initiative 2 Joint Undertaking.
- Published
- 2018
6. A T-cell-dependent antibody response study using a murine surrogate anti-PD-1 monoclonal antibody as an alternative to a non-human primate model.
- Author
-
Plitnick, Lisa M., Hutchins, Beth, Dubey, Sheri, Li, Nianyu, Amin, Rupesh P., Born, Stephanie, Mangadu, Ruban, Phillips, Joseph H., Sriram, Venkataraman, and Herzyk, Danuta J.
- Subjects
ANTIBODY formation ,PROGRAMMED cell death 1 receptors ,HEPATITIS B vaccines ,MONOCLONAL antibodies ,PRIMATES ,IMMUNE response ,BLOCK designs - Abstract
The programmed cell death 1 (PD-1) pathway represents a major immune checkpoint which may be engaged by cells in a tumor microenvironment to overcome active T-cell immune surveillance. Pembrolizumab (Keytruda
® ) is a potent and highly selective humanized monoclonal antibody (mAb) of the IgG4 /κ isotype designed to directly block the interaction between PD-1 and its ligands, PD-L1 and PD-L2. The current work was focused on developing a mouse T-Dependent Antibody Response (TDAR) model using a murinized rat anti-mouse PD-1 antibody (muDX400; a rodent surrogate for pembrolizumab) to evaluate the potential impact of treatment with a PD-1 inhibitor on immune responses to an antigen challenge (e.g. HBsAg in Hepatitis B vaccine). Despite the lower binding affinity and T1/2 compared to pembrolizumab, ligand blocking data indicated muDX400 had appropriate pharmacological activity and demonstrated efficacy in mouse tumor models, thus was suitable for pharmacodynamic and vaccination studies in mice. In a vaccination study in which mice were concomitantly administered muDX400 and the Hepatitis B vaccine, muDX400 was well-tolerated and did not result in any immune-mediated adverse effects. The treatment with muDX400 was associated with a shift in the ratio between naive and memory cells in both CD4+ and CD8+ T-lymphocytes in the spleen but did not affect anti-HBsAg antibody response profile. The mouse TDAR model using the Hepatitis B vaccine and the surrogate anti-PD1 monoclonal antibody was a useful tool in the evaluation of the potential immune-mediated effects of pembrolizumab following vaccination and appears to be a suitable alternative for the nonhuman primate TDAR models utilized for other checkpoint inhibitors. [ABSTRACT FROM AUTHOR]- Published
- 2020
- Full Text
- View/download PDF
7. A replication-defective human cytomegalovirus vaccine for prevention of congenital infection.
- Author
-
Dai Wang, Freed, Daniel C., Xi He, Fengsheng Li, Aimin Tang, Cox, Kara S., Dubey, Sheri A., Cole, Suzanne, Medi, Muneeswara Babu, Yaping Liu, Jingyuan Xu, Zhi-Qiang Zhang, Finnefrock, Adam C., Song, Liping, Espeseth, Amy S., Shiver, John W., Casimiro, Danilo R., and Tong-Ming Fu
- Subjects
CYTOMEGALOVIRUS diseases ,CONGENITAL disorders ,CYTOMEGALOVIRUSES ,VIRAL replication ,IMMUNOGLOBULINS ,VIRAL antigens ,VACCINATION - Abstract
The article discusses a study on the use of a replication-defective human cytomegalovirus vaccine to prevent congenital infection. The study examined a vaccine candidate with genetic modifications to improve its immunogenicity and attenuation. It used a synthetic compound named Shield-1 to regulate viral replication. The results revealed that the vaccine induced neutralizing antibodies to multiple viral antigens.
- Published
- 2016
- Full Text
- View/download PDF
8. Effector and central memory poly-functional CD4+ and CD8+ T cells are boosted upon ZOSTAVAX® vaccination.
- Author
-
Sei, Janet J., Cox, Kara S., Dubey, Sheri A., Antonello, Joseph M., Krah, David L., Casimiro, Danilo R., and Vora, Kalpit A.
- Subjects
CD4 antigen ,CD8 antigen ,VACCINATION - Abstract
ZOSTAVAX® is a live attenuated varicella-zoster virus (VZV) vaccine that is licensed for the protection of individuals ≥50 years against shingles and its most common complication, postherpetic neuralgia. While IFNγ responses increase upon vaccination, the quality of the T cell response has not been elucidated. By using polychromatic flow cytometry, we characterized the breadth, magnitude, and quality of ex vivo CD4
+ and CD8+ T cell responses induced 3-4 weeks after ZOSTAVAX vaccination of healthy adults. We show, for the first time that the highest frequencies of VZV-specific CD4+ T cells were poly-functional CD154+ IFNγ+ IL-2+ TNFα+ cells, which were boosted upon vaccination. The CD4+ T cells were broadly reactive to several VZV proteins, with immediate early (IE) 63 ranking the highest among them in the fold rise of poly-functional cells, followed by IE62, gB, open reading frame (ORF) 9, and gE. We identified a novel poly-functional ORF9-specific CD8+ T cell population in 62% of the subjects, and these were boosted upon vaccination. Poly-functional CD4+ and CD8+ T cells produced significantly higher levels of IFNγ, IL-2, and TNFα compared to mono-functional cells. After vaccination, a boost in the expression of IFNγ by poly-functional IE63- and ORF9-specific CD4+ T cells and IFNγ, IL-2, and TNFα by ORF9-specific poly-functional CD8+ T cells was observed. Responding poly-functional T cells exhibited both effector (CCR7-CD45RA-CD45RO+ ), and central (CCR7+ CD45RA-CD45RO+ ) memory phenotypes, which expressed com- parable levels of cytokines. Altogether, our studies demonstrate that a boost in memory poly-functional CD4+ T cells and ORF9-specific CD8+ T cells may contribute toward ZOSTAVAX efficacy. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
9. Vaccination with Ad5 Vectors Expands Ad5-Specific CD8+ T Cells without Altering Memory Phenotype or Functionality.
- Author
-
Hutnick, Natalie A., Carnathan, Diane G., Dubey, Sheri A., Cox, Kara S., Kierstead, Lisa, Makadonas, George, Ratcliffe, Sarah J., Lasaro, Marcio O., Robertson, Michael N., Casimiro, Danilo R., Ertl, Hildegund C. J., and Betts, Michael R.
- Subjects
VACCINATION ,T cells ,PHENOTYPES ,ANTIGENS ,IMMUNOGLOBULINS ,CYTOMETRY ,IMMUNIZATION ,LYMPHOCYTES ,GENETICS ,IMMUNITY - Abstract
Background: Adenoviral (Ad) vaccine vectors represent both a vehicle to present a novel antigen to the immune system as well as restimulation of immune responses against the Ad vector itself. To what degree Ad-specific CD8
+ T cells are restimulated by Ad vector vaccination is unclear, although such knowledge would be important as vector-specific CD8+ T cell expansion could potentially further limit Ad vaccine efficacy beyond Ad-specific neutralizing antibody alone. Methodology/Principal Findings: Here we addressed this issue by measuring human Adenovirus serotype 5 (Ad5)-specific CD8+ T cells in recipients of the Merck Ad5 HIV-1 vaccine vector before, during, and after vaccination by multicolor flow cytometry. Ad5-specific CD8+ T-cells were detectable in 95% of subjects prior to vaccination, and displayed primarily an effector-type functional profile and phenotype. Peripheral blood Ad5-specific CD8+ T-cell numbers expanded after Ad5-HIV vaccination in all subjects, but differential expansion kinetics were noted in some baseline Ad5-neutralizing antibody (Ad5 nAb) seronegative subjects compared to baseline Ad5 nAb seropositive subjects. However, in neither group did vaccination alter polyfunctionality, mucosal targeting marker expression, or memory phenotype of Ad5-specific CD8+ T-cells. Conclusions: These data indicate that repeat Ad5-vector administration in humans expands Ad5-specific CD8+ T-cells without overtly affecting their functional capacity or phenotypic properties. This is a secondary analysis of samples collected during the 016 trial. Results of the Merck 016 trial safety and immunogenicity have been previously published in the journal of clinical infectious diseases. [ABSTRACT FROM AUTHOR]- Published
- 2010
- Full Text
- View/download PDF
10. Adenovirus-specific immunity after immunization with an Ad5 HIV-1 vaccine candidate in humans.
- Author
-
O'Brien, Kara L., Liu, Jinyan, King, Sharon L., Sun, Ying-Hua, Schmitz, Joern E., Lifton, Michelle A., Hutnick, Natalie A., Betts, Michael R., Dubey, Sheri A., Goudsmit, Jaap, Shiver, John W., Robertson, Michael N., Casimiro, Danilo R., and Barouch, Dan H.
- Subjects
ADENOVIRUS diseases ,ADENOVIRUSES ,AIDS vaccines ,IMMUNITY ,IMMUNIZATION ,VACCINATION - Abstract
The immunologic basis for the potential enhanced HIV-1 acquisition in adenovirus serotype 5 (Ad5)-seropositive individuals who received the Merck recombinant Ad5 HIV-1 vaccine in the STEP study remains unclear. Here we show that baseline Ad5-specific neutralizing antibodies are not correlated with Ad5-specific T lymphocyte responses and that Ad5-seropositive subjects do not develop higher vector-specific cellular immune responses as compared with Ad5-seronegative subjects after vaccination. These findings challenge the hypothesis that activated Ad5-specific T lymphocytes were the cause of the potential enhanced HIV-1 susceptibility in the STEP study. [ABSTRACT FROM AUTHOR]
- Published
- 2009
- Full Text
- View/download PDF
11. Baseline Ad5 serostatus does not predict Ad5 HIV vaccine–induced expansion of adenovirus-specific CD4+ T cells.
- Author
-
Hutnick, Natalie A., Carnathan, Diane G., Dubey, Sheri A., Cox, Kara S., Kierstead, Lisa, Ratcliffe, Sarah J., Robertson, Michael N., Casimiro, Danilo R., Ertl, Hildegund C. J., and Betts, Michael R.
- Subjects
AIDS vaccines ,T cells ,ADENOVIRUS diseases ,VACCINATION - Abstract
The mechanisms underlying possible increased HIV-1 acquisition in adenovirus 5 (Ad5)-seropositive subjects vaccinated with Ad5–HIV-1 vectors in the Merck STEP trial remain unclear. We find that Ad5 serostatus does not predict Ad5-specific CD4
+ T cell frequency, and we did not observe durable significant differences in Ad5-specific CD4+ T cells between Ad5-seropositive and Ad5-seronegative subjects after vaccination. These findings indicate no causative role for Ad5-specific CD4+ T cells in increasing HIV-1 susceptibility in the STEP trial. [ABSTRACT FROM AUTHOR]- Published
- 2009
- Full Text
- View/download PDF
12. Serostatus cutoff levels and fold increase to define seroresponse to recombinant vesicular stomatitis virus – Zaire Ebola virus envelope glycoprotein vaccine: An evidence-based analysis.
- Author
-
Antonello, Joseph, Grant-Klein, Rebecca J., Nichols, Rick, Kennedy, Stephen B., Dubey, Sheri, and Simon, Jakub K.
- Subjects
- *
VESICULAR stomatitis , *EBOLA virus , *CLINICAL trial registries , *FISHER exact test , *VACCINES , *GLYCOPROTEINS , *VIRAL envelope proteins - Abstract
• Antibody response correlating with vaccination was used to define seroresponse. • P-values from Fisher's exact test were used to compare definitions of seroresponse. • Two-fold rise and SSCO of 200 EU/mL best differentiated vaccine/placebo recipients. The recombinant vesicular stomatitis virus – Zaire Ebola virus envelope glycoprotein (rVSVΔG-ZEBOV-GP) vaccine is a live recombinant vesicular stomatitis virus (VSV) where the VSV G protein is replaced with ZEBOV-GP. To better understand the immune response after receiving the rVSVΔG-ZEBOV-GP vaccine, the current analyses evaluated different definitions of seroresponse that differentiate vaccine and placebo recipients enrolled in a placebo-controlled clinical trial (PREVAIL; NCT02344407) in which a subset of the study participants had elevated baseline titers. Alternative values for serostatus cutoff (SSCO; 200–500 EU/mL) and/or fold rise (two- to five-fold) were applied to compare their ability to distinguish between participants receiving rVSVΔG-ZEBOV-GP or placebo. The results indicate that an SSCO of 200 EU/mL can be used to define seropositivity at baseline (i.e. pre-vaccination). The use of dual criteria of the same SSCO (200 EU/mL) together with a two-fold rise in antibody level from baseline provided the definition of seroresponse that maximized the statistical significance between vaccine recipients and placebo recipients post-vaccination. Clinical trial registration: NCT02344407. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
13. Preclinical and clinical development of a dengue recombinant subunit vaccine.
- Author
-
Manoff, Susan B., George, Sarah L., Bett, Andrew J., Yelmene, Michele L., Dhanasekaran, Govindarajan, Eggemeyer, Linda, Sausser, Michele L., Dubey, Sheri A., Casimiro, Danilo R., Clements, David E., Martyak, Timothy, Pai, Vidya, Parks, D. Elliot, and Coller, Beth-Ann G.
- Subjects
- *
DENGUE , *GLYCOPROTEINS , *FLAVIVIRUSES , *GENE expression , *DROSOPHILA , *CLINICAL trials , *VACCINATION - Abstract
This review focuses on a dengue virus (DENV) vaccine candidate based on a recombinant subunit approach which targets the DENV envelope glycoprotein (E). Truncated versions of E consisting of the N-terminal portion of E (DEN-80E) have been expressed recombinantly in the Drosophila S2 expression system and shown to have native-like conformation. Preclinical studies demonstrate that formulations containing tetravalent DEN-80E adjuvanted with ISCOMATRIX™ adjuvant induce high titer virus neutralizing antibodies and IFN-γ producing T cells in flavivirus-naïve non-human primates. The preclinical data further suggest that administration of such formulations on a 0, 1, 6 month schedule may result in higher maximum virus neutralizing antibody titers and better durability of those titers compared to administration on a 0, 1, 2 month schedule. In addition, the virus neutralizing antibody titers induced by adjuvanted tetravalent DEN-80E compare favorably to the titers induced by a tetravalent live virus comparator. Furthermore, DEN-80E was demonstrated to be able to boost virus neutralizing antibody titers in macaques that have had a prior DENV exposure. A monovalent version of the vaccine candidate, DEN1-80E, was formulated with Alhydrogel™ and studied in a proof-of-principle Phase I clinical trial by Hawaii Biotech, Inc. ( NCT00936429 ). The clinical trial results demonstrate that both the 10 μg and 50 μg formulations of DEN1-80E with 1.25 mg of elemental aluminum were immunogenic when administered in a 3-injection series (0, 1, 2 months) to healthy, flavivirus-naïve adults. The vaccine formulations induced DENV-1 neutralizing antibodies in the majority of subjects, although the titers in most subjects were modest and waned over time. Both the 10 μg DEN1-80E and the 50 μg DEN1-80E formulations with Alhydrogel™ were generally well tolerated. [ABSTRACT FROM AUTHOR]
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.